Contribute Try STAT+ Today

Rise and shine, folks, another busy day is on the way. We can tell because, once again, the short person is already hunched over a laptop for a new round of learning and the official mascot is bounding about the Pharmalot campus in search of varmints. As for us, we are busy doing the usual — brewing cups of stimulation and foraging for items of interest. What else would be doing? So here is the latest. We hope your journey goes well today and you conquer the world. Meanwhile, stay safe and stay in touch. …

This is the eve of a major speech by President Biden, but it’s anyone’s guess what he will say about drug pricing, STAT explains. Swirling rumors have roiled the pharmaceutical industry and Congress over the past week. Top leaders in Congress have no idea what the White House actually supports. Sound familiar? Democratic leaders in the White House and Congress clearly aren’t on the same page, a division reminiscent of the years-long infighting over policy under Republican leadership in Washington — an infighting Democrats often criticized.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.